U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT06993428) titled 'A Trial With EMP16 in Preparation for Late Phase Studies' on May 19.
Brief Summary: The goal of this clinical trial is to explore the impact of dietary fibre supplement in the form of Vi-Siblin(R) S (ispaghula seed coats), together with advice on proper healthy diet, on tolerability during dose-escalation of EMP16 in preparation for upcoming Phase III trials. It will also learn about the safety of EMP16. The main questions it aims to answer are:
* How does the combination of EMP16 plus Vi-Siblin(R) S compare with the combination of conventional orlistat plus placebo dietary fibre supplementation on tolerability during dose-escalatio...